OMALIZUMAB
omalizumab 150 mg/mL injection, 1 mL syringe
OMALIZUMAB (10968G)
10968G
Manner of administration:Injection
Restriction
Indication: Uncontrolled severe allergic asthma
Treatment phase: Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new
treatment cycle following a break in PBS-subsidised biological medicine therapy)
Restriction
Indication: Uncontrolled severe allergic asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 6 | DPMQ: $226.31 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Omlyclo | |||||